

PRESS RELEASE

New Analytical Case Study Reveals Longevity Deficits and Health and Wealth Shortfalls in America

Joint Special Analytical Case Study Between Aging Analytics Agency
and the Targeting Metabesity Conference Series Identifies and Clarifies
the Current Longevity Policy Deficits of the United States of America



October 15, 2019, London, UK: "*Metabesity and Longevity: USA Special Case Study*" is an open-access analytical report produced by [Aging Analytics Agency](#) and [Targeting Metabesity 2019](#) to examine the links between metabesity, Longevity and the USA's current health shortfalls, including low health-adjusted life expectancy (HALE) and the large gap between HALE and life expectancy, despite its extremely high per-capita healthcare expenditures, and to chart policy recommendations to neutralize this vast health vs wealth deficit.

“We at Kinexum are elated by the strategic relationship forged with the Aging Analytics Agency of Deep Knowledge Ventures. We are honored to have collaborated with our Aging Analytics Agency colleagues to produce this milestone report and call to action,” said **Zan Fleming, Founder and Executive Chairman, Kinexum (the organizer of Targeting Metabesity)**.

[Targeting Metabesity 2019](#) conference focuses on the prevention of noncommunicable diseases and the treatment of age-related health dysfunctions to extend health-adjusted life expectancy. The conference, to be held October 15-16, 2019 at the Carnegie Institution for Science in Washington, D.C., will address one of the important issues in healthcare: the constellation of major chronic diseases, including diabetes, cardiovascular disease, dementia, cancer, and the aging process, that are considered to be the “[slow motion disaster](#)”. The event will feature many notable speakers, including top researchers in geroscience, diabetes, cancer, and other chronic diseases, directors of several National Institutes of Health and Centers at the Food and Drug Administration, leaders of both established and emerging companies and venture capital, and others. For more information, see the [speakers list](#).

Metabesity denotes the common metabolic roots behind some of the most prevalent and costly degenerative diseases burdening the USA economy today. Much of biological aging, which is the largest risk factor for such diseases, can be considered as a disintegration of normal metabolic functioning and coordination. This means that the most effective and economic approach to healthcare necessarily involves the prevention of costly chronic diseases by intervening upon their shared metabolic roots as early as possible, to prevent rather than to treat.

Fortunately, science has made large leaps and bounds in identifying the common metabolic and aging-related roots to the most prevalent and costly diseases afflicting Americans today – and the tools, techniques and technologies capable of intervening at those roots in order to extend healthspan, and to compress the incidence of such diseases into the final years of life. **Dr. Michael Zemel, CSO, NuSirt Biopharma** commented: *“Therapies for extending health-span are on the near-term horizon and are well within reach provided there is a receptive regulatory environment to manage them. Longevity extension, on the other hand, may seem difficult to impossible, but in reality this “impossibility” will just take a little longer in a supportive environment for clinical development.”*

As the issue of aging population intensifies, sick care will become increasingly expensive and ineffective. The USA needs to rapidly deploy a government-led shift from treatment to prevention, and from prevention to precision health, using deep diagnostics and prognostics in combination with biomarkers of aging, metabesity, health and intervention-effectiveness, to delay the onset of disease with as minimal intervention as possible, as early as possible. *“The drugs and treatments that have resulted from America’s commitment to medical science have benefited – and saved – countless lives. In order to continue leading the world in biomedical innovation, America’s policymakers and regulators must recognize the importance of longevity research and work to clear the federal roadblocks preventing this new era of medicine from reaching the hands of the public,”* said **Breanna Deutsch, former Press Secretary and Communications Director for the U.S. Congress**.

Seeking synergies between Longevity research, P4 medicine and Artificial Intelligence has the potential to enable rapid and widespread policy and infrastructural reforms for USA healthcare to quickly boost National Healthy Longevity, but only with sufficient government commitment. *"As was the case at the cusp of the moon shot or the human genome project, it seems increasingly a question of when, not if, emerging science will enable us to slow or even reverse human aging,"* **Thomas Seoh, President and CEO, Kinexum** said. *"What we need now is socioeconomic and policy alignment to accelerate the translation of this emerging science into material, accessible gains in public health. Preventing chronic diseases and extending health span constitute some of the most leveraged opportunities in healthcare in coming decades."*

The USA holds the greatest share of the multi-trillion dollar global Longevity economy and the majority share of global Longevity Industry companies and players. It also has one of the highest rates of healthcare expenditures. The USA has all the resources necessary to become a global leader in Longevity, Preventive Medicine and Precision Health, and of National Healthy Longevity, but lacks national prioritization by its federal government, and a strategy to unite the activities of its Longevity Industry, AI, and Preventive Medicine industry ecosystems to work in synergy, rather than in discoordination. The USA's low HALE and high gap between HALE and LE is not a scientific problem, it is a policy problem.

About Aging Analytics Agency

Aging Analytics Agency is the world's premier provider of industry analytics on the topics of Longevity, Precision Preventive Medicine and Economics of aging, and the convergence of technologies such as AI and Digital Health and their impact on healthcare. The company provides strategic consulting services in fields related to Longevity, and currently serves as the primary source of analytics for the specialized hybrid hedge fund Longevity.Capital, as well as the UK All-Party Parliamentary Group for Longevity.

Email: info@aginganalytics.com | Web: www.aginganalytics.com

About Targeting Metabesity 2019

Targeting Metabesity 2019 focuses on shifting the emphasis from treatment to prevention, and going beyond managing individual diseases to extending healthy lifespan. The conference brings together stellar speakers and participants from science and medicine, government regulation and policy, health care organizations, industry (drugs, devices, nutritional, and digital products), capital markets, patient advocacy, and other fields and is held this year at the Carnegie Institution for Science in Washington, DC, 15-16 October 2019.

Email: cmq@custommanagement.com | Web: www.metabesity2019.com